Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Original Date: 
February 2016
Revised Date: 
December 2019
  • Treatment of convulsive status epilepticus
  • Short term parenteral replacement for oral levetiracetam
Reconstitution and Stability: 
  • Available as 500 mg/5 mL (100 mg/mL) clear solution -  product with particulate matter or discoloration should not be used
  • Store at room temperature
  • Single use vial - use immediately after opening and discard unused portion
  • Diluted solution in 0.9% NaCl  (40 mg/mL) stable 14 days refrigerated

- Solutions Compatible: D5W, 0.9% NaCl, Lactated Ringer's - stable 24 hours at room temperature

- Additive compatible: diazepam, lorazepam, valproic sodium


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct NO
IV Intermittent Infusion

Usual dilution: 40 mg/mL for doses greater than or equal to 200 mg

- 20 mg/mL for doses less 200 mg
Infusion time: 15 minutes

IV Continuous Infusion NO



(For neonatal dosages, refer to Neonatal IV Drug Manual.)

** total daily intravenous dosage should be equivalent to the total daily dosage and frequency of the oral administration **


  • Loading dose:  20 - 40 mg /kg/dose x1
    Dose limit:  60 mg/kg/dose or 3000 mg/dose
  • Initial maintenance dose: 5 - 10 mg/kg/day divided Q12H
  • May increase dose every 1 - 2 weeks to 40 - 60 mg/kg/day divided Q12H
    Dose limit:  100 mg/kg/day or 3000 mg/day, whichever is less


  • 1000 mg/day divided Q12H (Maximum: 3000 mg/day)
  • May be diluted in 100 mL bag of D5W, 0.9%NaCl, or Lactated Ringer's and administered over 15 minutes


  • Dosage should be reduced in patients with moderate and severe impairment - refer to available references or clinical pharmacist for dosage adjustment
Potential hazards of parenteral administration: 
  • Central nervous system: sedation, dizziness, irritability, behavioural changes, headache
  • Dermatologic: rash (some cases of Stevens-Johnson Syndrome reported)
  • Hematologic: decreased RBC, hematocrit, hemoglobin, neutrophils
  • Monitoring:
    Prior to administration:
    - Baseline vital signs: respiratory rate, heart rate, blood pressure
    - Renal function
    - CBC
    - Sensitivity to levetiracetam

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.